Profile for China Patent: 101861146

US Patent Family Members and Approved Drugs for China Patent: 101861146

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide
	May 13, 2029	Vifor Fresenius	VELPHORO	ferric oxyhydroxide

Key insights for pharmaceutical patentability - China patent CN101861146

Last updated: April 25, 2026

What is the scope of CN101861146 and how does it sit in the China drug patent landscape?

CN101861146 is a China patent publication that, based on its bibliographic identifiers, falls under the country-level patent system and is part of the CN publication family ecosystem. However, no claim text, assignee, title, priority data, classification, status, or legal events are provided in the prompt, and without those inputs it is not possible to produce a complete and accurate claim-by-claim scope map or a defensible landscape view.

No further analysis can be generated under the operating constraints.

---

Key Takeaways

• CN101861146 scope and claims cannot be determined from the information provided.
• A reliable China drug patent landscape requires claim text, bibliographic data, legal status, and citation history; none are available in the prompt.
• Producing a landscape without those elements would risk incorrect attribution of scope, term, exclusivity, and competitive relevance.

---

FAQs

1. Can you summarize CN101861146 claim scope without the claim set or title?
   No. Claim scope must be derived from the actual claims and description.

2. Can you map the CN101861146 family and term without priority and legal status?
   No. Family construction and term modeling require priority, publication dates, and legal events.

3. Can you assess freedom-to-operate around CN101861146 without identifying the drug and jurisdictional coverage?
   No. FTO requires the active ingredient, formulation, and claim boundaries, plus status.

4. Can you list relevant citing patents or competitors without citation data?
   No. A landscape requires CPC/IPC and citation graph inputs.

5. Can you determine exclusivity or regulatory linkage impact without prosecution and status records?
   No. Exclusivity and linkage depend on legal status, grant, and regulatory filings.

---

References

No sources were provided in the prompt, so no citations can be generated.